References
- 1. Creamer D, Walsh SA, Dziewulski P et al. U.K. Guidelines for the Management of Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis in Adults 2016. Br J Dermatol 2016; 174(6):1194-1227.10.1111/bjd.1453027317286
- 2. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necolysis. Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol 2013; 69:173.e1-13.10.1016/j.jaad.2013.05.00323866878
- 3. Sassolas B, Haddad C, Mockenhaupt M et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case–control analysis. Clin Pharmacol Ther 2010; 88:60–8.10.1038/clpt.2009.25220375998
- 4. Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents – a 6 year series from Chandigarh. India J Postgrad Med 2001; 47:95–9.
- 5. Viard-Leveugle I, Gaide O, Jankovic D et al. TNFα and IFNγ are potential inducers of Fasmediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol 2013; 133:489–98.10.1038/jid.2012.33022992806
- 6. Caproni M, Antiga E, Parodi A et al. Elevated circulating CD40 ligand in patients with erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 2006;154:1006-7.10.1111/j.1365-2133.2006.07211.x16634916
- 7. Chung WH, Hung SI, Yang JY et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008;14:1343-50.10.1038/nm.188419029983
- 8. Abe R, Yoshioka N, Murata J, Fujita Y, Shimizu H. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med 2009;151:514-5.10.7326/0003-4819-151-7-200910060-0001619805776
- 9. Abe R. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of the diseases. J Dermatol Sci 2008;52:151-9.10.1016/j.jdermsci.2008.06.00318657400
- 10. Bastuji-Garin S, Fouchard N, Bertocchi M et al. SCORTEN: a severityofillness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115:149–53.10.1046/j.1523-1747.2000.00061.x10951229
- 11. Mahar PD, Wasiak J, Hii B et al. A systematic review of the management and outcome of toxic epidermal necrolysis treated in burns centres. Burns 2014; 40:1245–54.10.1016/j.burns.2014.02.00624685065
- 12. Aihara M, Kano Y, Fujita H et al. Efficacy of additional i.v. immunoglobulin to steroid therapy in StevensJohnson syndrome and toxic epidermal necrolysis. J Dermatol 2015; 42:768–77.10.1111/1346-8138.1292525982480
- 13. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for StevensJohnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007; 87:144–8.10.2340/00015555-021417340021